<< Cancer Genome Atlas funds study for analysis and interpretation of tumor genetic data | Healthcare providers to incorporate new technologies to improve their business and patient care >>
Read in | English | Português | Ελληνικά

HTDS' Hepatitis A vaccine receives GMP Certificate from the Russian FDA

Published on October 8, 2009 at 2:57 AM · No Comments

HTDS www.htdsmedical.com (HTDS) - The issuer's China based operating subsidiary Mellow Hope www.mellowhope.com is pleased to announce that its Hepatitis A Live Attenuated Vaccine (Brand name: Mevac-A) associate operation plant has obtained the GMP Certificate (Good Manufacturing Practice See Description http://en.wikipedia.org/wiki/Good_manufacturing_practice) from the Russian FDA. http://www.who.int/hiv/HIVCP_RUS.pdf

Since on or about September 24, 2009 when Mellow Hope announced through its exclusive business partner Zhejiang Tianyuan Bio-pharmaceutical Co., Ltd http://www.ty-pharm.com/en/index.asp that it has been granted H1N1 license by SFDA (China Authority) http://eng.sfda.gov.cn/eng interests in H1N1 began to grow Internationally with the company. Mellow Hope is the exclusive agent of Zhejiang Tianyuan Bio-pharmaceutical Co., Ltd for International marketing and sales.

New contracts and sales progress on H1N1 will be disclosed as they occur in subsequent HTDS press releases.

In other company news and events the company with this release brings attention to its Pink Sheets filing dated October 6, 2009 Supplemental Information- Forward Stock Split 2-1 HTDS Naked Short Positions and Remedies.

In summary, HTDS is considering having its shareholders approve a resolution on to make a two for one stock forward split. After due consideration, HTDS directors are recommending that the shareholders approve amending and restating our Articles of Incorporation in order to consolidate numerous amendments in the Articles that have occurred over the years, to create a two-for-one forward split, to prepare the Company to move up to the OTC Bulletin Board, and to add certain anti-takeover and other provisions. HTDS sees this forward split as one way to force short sellers to cover their current positions. Other remedies are also under consideration to thwart the short sellers or "oversold" positions of HTDS.

To receive regular updates on HTDS please sign up or opt in with your email address at this link http://www.minamargroup.com/updates/

SOURCE Hard to Treat Diseases

Posted in: Pharmaceutical News

Tags: , , , ,

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading